The weight loss consists mainly of fat mass—approximately 2/3 according to several studies—results that highlight the impact of this class of antidiabetic drugs in improving body composition in patients with T2D, alongside the beneficial results related to waist circumference (WC), body mass index (BMI), subcutaneous fat area and visceral fat area, with improved insulin sensitivity, lower values of fasting insulin, reduction in hepatic steatosis and quantitative and qualitative improvements of LDL and high-density lipoprotein (HDL) particles [10,14,33,34,35,36,37,38,39]. The gene discussed is INS; the disease is Hepatic steatosis.